Amedisys 2010 third quarter Net service revenue increases 4.2% to $404.7 million

NewsGuard 100/100 Score

Amedisys, Inc. (NASDAQ: AMED), a leading home health and hospice company, today reported its financial results for the three and nine-month periods ended September 30, 2010. Net service revenue increased 4.2% while net income attributable to Amedisys, Inc., decreased 39.8% compared to the three-month period ended September 30, 2009.

Three-Month Periods Ended September 30, 2010 and 2009

• Net service revenue increased $16.4 million or 4.2% to $404.7 million compared to $388.3 million in 2009, with $8.4 million of the increase related to growth through base/start-up agencies.

• Net income attributable to Amedisys, Inc. decreased $14.3 million or 39.8% to $21.6 million compared to $35.9 million in 2009.

• Diluted earnings per share decreased 41.0% to $0.76 compared to $1.29 per diluted share in 2009. The weighted average number of diluted shares outstanding increased to approximately 28.5 million compared to 27.9 million in 2009.

• Earnings before interest, taxes, depreciation and amortization ("EBITDA") decreased 32.7% to $46.5 million compared to $69.1 million in 2009.

• After adding back $6.3 million ($3.8 million, net of income tax) or $0.13 per diluted share in certain items*, the following would have been our adjusted results:

  • Net income attributable to Amedisys, Inc. decreased 29.1% to $25.5 million compared to $35.9 million in 2009.
  • Diluted earnings per share decreased 31.0% to $0.89 compared to $1.29 per diluted share in 2009.
  • EBITDA decreased 24.9% to $51.9 million compared to $69.1 million in 2009.

Nine-Month Periods Ended September 30, 2010 and 2009

• Net service revenue increased $132.0 million or 11.9% to $1.2 billion compared to $1.1 billion in 2009, with $100.7 million of the increase related to growth through base/start-up agencies.

• Net income attributable to Amedisys, Inc. decreased $7.6 million or 7.7% to $90.5 million compared to $98.0 million in 2009.

• Diluted earnings per share decreased 10.4% to $3.18 compared to $3.55 per diluted share in 2009. The weighted average number of diluted shares outstanding increased to approximately 28.5 million compared to 27.6 million in 2009.

• EBITDA decreased 5.2% to $180.6 million compared to $190.4 million in 2009.

• After adding back $7.5 million ($4.6 million, net of income tax) or $0.16 per diluted share in certain items*, the following would have been our results:

  • Net income attributable to Amedisys, Inc. decreased 3.1% to $95.0 million compared to $98.0 million in 2009.
  • Diluted earnings per share decreased 5.9% to $3.34 compared to $3.55 per diluted share in 2009.
  • EBITDA decreased 1.7% to $187.2 million compared to $190.4 million in 2009.

* See footnote 2 on page 7 for explanation of these certain items.

William F. Borne, Chief Executive Officer of Amedisys, Inc. stated, "The quarter's results reflect the volume fall-off we began experiencing in the second quarter. We have implemented a number of initiatives to better align our cost structure with current volume and improve our revenue moving forward. We continue to invest in delivering the highest quality care with a focus on operational efficiency and believe the long term prospects for the company are strong. These actions will better position the company moving forward."

Updated 2010 Guidance

  • Net service revenue is anticipated to be in the range of $1.625 billion to $1.645 billion, excluding the effects of future acquisitions, if any are made.
  • Diluted earnings per share is expected to be in the range of $4.20 to $4.35 based on an estimated 28.8 million shares outstanding. This guidance does not include the effects of any share repurchases or the effects of future acquisitions, if any are made.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.